Efficacy and Tolerability of a Single-Pill Combination of Amlodipine/Valsartan in Asian Hypertensive Patients Not Adequately Controlled with Valsartan Monotherapy
Source: Clinical and Experimental Hypertension, Volume 33, Number 3, May 2011 , pp. 179-186(8)
Publisher: Informa Healthcare
Abstract:This randomized, double-blind study evaluated efficacy of a single-pill combination of amlodipine/valsartan (Aml/Val) in Asian patients with hypertension not responding to Val 80 mg. Patients with mean sitting diastolic blood pressure (DBP) ≥≥90 −− ≤≤110 mmHg were randomized to Aml/Val 5/80, Val 80, or Val 160 mg for 8 weeks. At week-8 endpoint, significantly greater reductions in BP were seen with Aml/Val 5/80 mg than valsartan monotherapies (p < 0.0001). The BP control was greater with Aml/Val 5/80 (70.5%%) than Val (44.1––58.6%%) monotherapies. The combination was well tolerated. In conclusion, single-pill combination with Aml/Val provided significant additional BP reduction and control in hypertensive patients not responding to Val 80 mg.
Document Type: Research Article
Affiliations: 1: 1The First Affiliated Hospital with Nanjing Medical University, Nanjing, China 2: 2Peking University People's Hospital, Beijing, China 3: 3The Second Hospital of Hebei Medical University, Shijiazhuang, China 4: 4Zhongshan Hospital Fudan University, Shanghai, China 5: 5Beijing Novartis Pharma Co Ltd, Beijing, China 6: 6Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Publication date: May 1, 2011